Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
PCVX
Vaxcyte
Market cap
$6.83B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | GMAB | PCVX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 15F | GMAB |
| Benjamin Graham | 64C | 46D | GMAB |
| Philip Fisher | 48D | 36D | GMAB |
| Peter Lynch | 25F | 11F | GMAB |
| Joel Greenblatt | 76B | 0F | GMAB |
| Charlie Munger | 68C | 25F | GMAB |
| Terry Smith | 71C | 30F | GMAB |
| Metric | GMAB | PCVX |
|---|---|---|
| Market cap | $16.5B | $6.83B |
| P/E (TTM) | 6.2x | - |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -34.98% |
| Gross margin | 93.88% | 0.0% |
| Net margin | 18.23% | 0.0% |
| Revenue CAGR 5y | -18.45% | - |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
PCVX leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.